About

Chong is a Principal at F-Prime Capital.  He focuses primarily on biopharmaceutical and medical technology sectors and works closely with the Eight Roads Ventures Asia team to manage portfolio companies and new investment opportunities in China.  Prior to joining F-Prime in 2015, Chong was an associate in McKinsey and Company’s Boston office, a hedge fund healthcare equity analyst with Massif Partners and Affirmed Healthcare, and a researcher focusing on developmental neurobiology at Temasek Life Sciences Laboratory in Singapore.

Chong holds a Ph.D. in Cell Biology from University of Virginia and a MBA from Darden School of Business, University of Virginia.  He received his B.S. in biology from Zhejiang University, China.

  • Adagene is an antibody discovery and engineering company with proprietary Smart Antibody Technology, which increases success rates, substantially accelerates time to market, and reduces the costs associated with developing a therapeutic antibody. Learn more at www.adagene.com.

  • b-ONE Ortho Corp. is an emerging orthopedic technology company dedicated to the development of innovative orthopedic healthcare solutions that restore patient mobility and improve surgical outcomes. Every day we are committed to becoming the most credible choice for orthopedic products worldwide. Learn more at http://www.b1.co/.

  • Zhejiang Bang Er Medical Investment Management Co., Ltd. is a leading private medical service provider that operates several private hospitals specializing in orthopedic care and related services in China. Learn more at www.zjbanger.com.

    • Category

      • Health IT/Services
    • Status

      • Private
    • Location

      Zhejiang, China

    • Year Invested

      2015

    • Team

  • Better Life Medical is a fully-integrated hearing aid manufacturer developing and commercializing novel digital programmable hearing aid solutions for the Chinese market. Learn more at www.goblm.com.cn/.

  • BioRegen Biomedical is a fully integrated medical product company based on a proprietary technology platform. BioRegen is developing and commercializing high quality hyaluronic acid (“HA”) based products for the Chinese market. Learn more at www.bioregenmed.com.

    • Category

      • MedTech
    • Status

      • Private
    • Location

      China

    • Year Invested

      2010

    • Team

  • Eyebright Medical Technology Co., Ltd. is an emerging leader in the ophthalmologic device market in China. Learn more at www.ebmedical.com.

    • Category

      • MedTech
    • Status

      • Private
    • Location

      Beijing, China

    • Year Invested

      2015

    • Team

  • Health Technology is a mobile platform for hospitals that connects patients, optimizes the patient’s hospital visit experience, and streamlines administrator workflow. Learn more at www.gzhc365.com.

    • Category

      • Health IT/Services
    • Status

      • Private
    • Location

      Guangzhou, China

    • Year Invested

      2016

    • Team

  • Innovent Biologics (1801.SS) has built a robust pipeline of innovative and commercially promising monoclonal antibodies and other biologics in the fields of oncology, ophthalmology, autoimmune, and cardiovascular diseases. Learn more at www.innoventbio.com.

  • Orient Speech Therapy Limited (“OST”) is a Hong-Kong based healthcare services provider that operates a chain of private speech therapy clinics in China. Learn more at www.dfqy.com.

  • Semma Therapeutics is a regenerative medicine company founded to develop transformative stem cell-derived therapies to provide a functional cure for patients with diabetes. Learn more at www.semma-tx.com/.

  • Wanhu provides integrated pharmacy benefit management services in China to better manage drug use and control costs. Learn more at www.wanhuhealth.com.

    • Category

      • Health IT/Services
    • Status

      • Private
    • Location

      China

    • Year Invested

      2017

    • Team